Dynamics of chronic myeloid leukaemia. (Q40403398)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15988530%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

title

Dynamics of chronic myeloid leukaemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15988530%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15988530%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

7

Martin A Nowak

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15988530%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

1

Franziska Michor

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15988530%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

author name string

Timothy P Hughes

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15988530%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

Susan Branford

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15988530%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

Neil P Shah

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15988530%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

Charles L Sawyers

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15988530%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

publication date

1 June 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15988530%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

language of work or name

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15988530%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

volume

435

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15988530%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

issue

7046

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15988530%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

page(s)

1267-1270

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15988530%20AND%20SRC:MED&resulttype=core&format=json

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

13 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

Purification and characterization of mouse hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

Discontinuation of imatinib therapy after achieving a molecular response

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

DNA replication fidelity

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03669

7 January 2021

Identifiers

DOI

10.1038/NATURE03669

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15988530%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

13 January 2020

1032868309

0 references

1 reference